NT5E and neoplasm: Enhancing the immune lymphocyte recruitment and activation against tumours, by transfecting OVs with deubiquitinating enzyme genes and reversing the anti-inflammatory effects of CD73, may be novel ways of improving the current outcomes of OVTs.